https://assets.capyfin.com/instruments/678fdc13234e27009c5d62b2.png avatar
Lifecore Biomedical
🇺🇸 NASDAQ:LFCR
View Company
OverviewEarningsDividends
•
Feb 27, 2022

Lifecore Biomedical Q3 2022 Earnings Report

Landec Corporation reported an increase in Lifecore segment revenues and reiterated fiscal 2022 full year guidance.

Key Takeaways

Landec Corporation reported an 18.8% increase in revenues, driven by a 27.9% increase in Lifecore segment revenues. The company's net loss from continuing operations was $7.1 million, which includes $4.6 million of restructuring and other non-recurring charges. The company is reiterating its previously announced guidance on a pro forma consolidated basis, and at the segment level.

Revenues increased 18.8% year-over-year to $53.1 million.

Gross profit decreased 3.8% year-over-year to $13.9 million, primarily due to the timing and revenue mix at Lifecore.

Net loss from continuing operations was $7.1 million, including $4.6 million of restructuring and other non-recurring charges.

Lifecore segment revenues increased 27.9% in fiscal third quarter, as compared to prior year period

Total Revenue
$53.1M
Previous year: $138M
-61.5%
EPS
-$0.08
Previous year: -$0.09
-11.1%
Adjusted EBITDA
$6.36M
Previous year: $7.61M
-16.4%
Gross Profit
$13.9M
Previous year: $19.7M
-29.4%
Cash and Equivalents
$1.85M
Previous year: $2.25M
-17.5%
Free Cash Flow
-$25.7M
Previous year: -$11.8M
+116.9%
Total Assets
$326M
Previous year: $510M
-36.1%

Lifecore Biomedical

Lifecore Biomedical

Lifecore Biomedical Revenue by Segment

Forward Guidance

The Company is reiterating its previously announced guidance on a pro forma consolidated basis, and at the segment level.

Positive Outlook

  • Pro forma consolidated revenue is expected to be in the range of $179 million to $185 million (+4% to +8%).
  • Lifecore segment revenue is expected to be in the range of $105 million to $108 million (+7% to +10%).
  • Pro forma Curation Foods segment revenue is expected to be in the range of $74 million to $77 million (+1% to +5%).
  • Pro forma consolidated adjusted EBITDA is expected to be in the range of $20.5 million to $23 million (+10% to +24%).
  • Lifecore segment adjusted EBITDA is expected to be in the range of $26 million to $27 million (+6% to +10%).

Challenges Ahead

  • Guidance continues to reflect the Curation Foods’ Eat Smart Disposition on December 13, 2021.
  • Incremental inflationary and supply chain headwinds within the remaining Curation Foods business.
  • Pro forma Curation Foods segment adjusted EBITDA is expected to be in the range of $3 million to $4 million (flat to +33%).
  • Other (Corporate Expense) is expected to be in the range of ($8.0) million to ($8.5) million.
  • Reflects a $3.5 million reallocation of corporate expense from the Eat Smart Disposition to the Other segment

Company Overview

Full financial data and analysis

View Lifecore Biomedical